The pharmacogenomics market size has grown rapidly in recent years. It will grow from $9.84 billion in 2025 to $10.85 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing genomic research activities, expansion of targeted therapy development, rising prevalence of chronic diseases, improvements in sequencing technologies, growing availability of genetic testing services.
The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $15.98 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments in precision medicine programs, rising adoption of AI-driven genomic analysis, expansion of pharmacogenomics in oncology and cardiology, growing focus on individualized drug development, continuous advancements in bioinformatics platforms. Major trends in the forecast period include increasing adoption of personalized medicine approaches, rising use of genetic testing in drug selection, growing integration of pharmacogenomic data in clinical workflows, expansion of companion diagnostics, enhanced focus on precision therapeutics.
The rising prevalence of chronic diseases is expected to support the expansion of the pharmacogenomics market in the coming years. Chronic diseases are long-term medical conditions that typically require continuous management throughout a patient’s life. Their growing incidence is largely attributed to increased life expectancy worldwide, along with the widespread adoption of behavioral risk factors such as physical inactivity, unhealthy dietary habits, and tobacco consumption. Pharmacogenomics enables a tailored treatment approach for chronic conditions by considering individual genetic differences that influence how patients respond to medications. For example, in 2025, data from the International Diabetes Federation indicated that in 2024 approximately 589 million adults aged 20-79 were living with diabetes, with this number projected to rise to 853 million by 2050. Additionally, more than four out of five adults with diabetes were reported to be residing in low- and middle-income countries. As a result, the growing burden of chronic diseases is contributing significantly to the adoption of pharmacogenomics solutions.
Companies operating in the pharmacogenomics space are increasingly emphasizing artificial intelligence (AI)-based models that can identify and manage drug-drug interactions at the genomic level, thereby enhancing medication safety, minimizing adverse effects, and supporting more precise prescribing decisions. AI-powered pharmacogenetics platforms are advanced digital systems that apply artificial intelligence to evaluate an individual’s genetic profile and predict drug response. For instance, in December 2024, PGxAI, a United States-based AI-driven pharmacogenetics company, introduced its Sirius model, an AI-enabled pharmacogenetics engine designed to personalize drug selection, dosage, and drug-drug interaction management based on genomic data. Sirius supports 730 drugs and 40 major pharmacogenes, offering significantly broader coverage compared to conventional pharmacogenomic tools. The platform is intended for use by hospital networks, diagnostic laboratories, and clinical research organizations, with the aim of reducing adverse drug reactions and improving overall therapeutic outcomes.
In June 2023, Genomenon, a U.S.-based genomics intelligence company, acquired Boston Genetics for an undisclosed amount. This strategic acquisition combines Genomenon's AI-powered genomic platform with Boston Genetics' genetic scientists to comprehensively curate the human genome. The acquisition strengthens clinical diagnostic and pharmaceutical drug development programs by providing valuable insights into the genomic drivers of genetic diseases and oncology. Additionally, it establishes a genomics data service arm for Genomenon, offering cost-effective variant curation team extensions for genetic testing labs, expediting turnaround times. Boston Genetics, a genomics interpretation and curation company based in the U.S., is part of this acquisition.
Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos.
North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmacogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the pharmacogenomics market by increasing costs of imported sequencing instruments, reagents, analytical software, and high-performance computing components. Research institutions and hospitals in North America and Europe are most affected due to reliance on specialized imported technologies, while Asia-Pacific faces higher costs for genomic tool manufacturing. These tariffs are increasing research expenditures and slowing equipment upgrades. However, they are also encouraging domestic development of sequencing technologies, regional bioinformatics innovation, and localized production of genomic research tools.
The pharmacogenomics market research report is one of a series of new reports that provides pharmacogenomics market statistics, including pharmacogenomics industry global market size, regional shares, competitors with a pharmacogenomics market share, detailed pharmacogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenomics industry. This pharmacogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Pharmacogenomics is a research field that explores how a patient's genes influence their response to medications. Its ultimate goal is to assist doctors in selecting the most appropriate drugs and doses tailored to each individual. Pharmacogenomics is instrumental in developing personalized drugs to address various health conditions, including cardiovascular disease, Alzheimer's disease, cancer, and asthma. The term 'pharmacogenomics marker' refers to a precise medical treatment approach for individuals or specific groups.
Key technologies employed in the pharmacogenomics market include next-generation sequencing (NGS), polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and others. NGS, a massively parallel sequencing technology, offers ultra-high throughput, scalability, and speed, enabling the determination of nucleotide order in entire genomes or specific DNA/RNA regions. Pharmacogenomics applications span neurological diseases, infectious diseases, oncology, cardiovascular diseases, pain management, and various other areas. End-users encompass hospitals and clinics, research institutions, academic institutes, and others.
The pharmacogenomics market includes revenues earned by entities by PennCNV,QuantiSNP, GenoCN and Nexus.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $15.98 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments in precision medicine programs, rising adoption of AI-driven genomic analysis, expansion of pharmacogenomics in oncology and cardiology, growing focus on individualized drug development, continuous advancements in bioinformatics platforms. Major trends in the forecast period include increasing adoption of personalized medicine approaches, rising use of genetic testing in drug selection, growing integration of pharmacogenomic data in clinical workflows, expansion of companion diagnostics, enhanced focus on precision therapeutics.
The rising prevalence of chronic diseases is expected to support the expansion of the pharmacogenomics market in the coming years. Chronic diseases are long-term medical conditions that typically require continuous management throughout a patient’s life. Their growing incidence is largely attributed to increased life expectancy worldwide, along with the widespread adoption of behavioral risk factors such as physical inactivity, unhealthy dietary habits, and tobacco consumption. Pharmacogenomics enables a tailored treatment approach for chronic conditions by considering individual genetic differences that influence how patients respond to medications. For example, in 2025, data from the International Diabetes Federation indicated that in 2024 approximately 589 million adults aged 20-79 were living with diabetes, with this number projected to rise to 853 million by 2050. Additionally, more than four out of five adults with diabetes were reported to be residing in low- and middle-income countries. As a result, the growing burden of chronic diseases is contributing significantly to the adoption of pharmacogenomics solutions.
Companies operating in the pharmacogenomics space are increasingly emphasizing artificial intelligence (AI)-based models that can identify and manage drug-drug interactions at the genomic level, thereby enhancing medication safety, minimizing adverse effects, and supporting more precise prescribing decisions. AI-powered pharmacogenetics platforms are advanced digital systems that apply artificial intelligence to evaluate an individual’s genetic profile and predict drug response. For instance, in December 2024, PGxAI, a United States-based AI-driven pharmacogenetics company, introduced its Sirius model, an AI-enabled pharmacogenetics engine designed to personalize drug selection, dosage, and drug-drug interaction management based on genomic data. Sirius supports 730 drugs and 40 major pharmacogenes, offering significantly broader coverage compared to conventional pharmacogenomic tools. The platform is intended for use by hospital networks, diagnostic laboratories, and clinical research organizations, with the aim of reducing adverse drug reactions and improving overall therapeutic outcomes.
In June 2023, Genomenon, a U.S.-based genomics intelligence company, acquired Boston Genetics for an undisclosed amount. This strategic acquisition combines Genomenon's AI-powered genomic platform with Boston Genetics' genetic scientists to comprehensively curate the human genome. The acquisition strengthens clinical diagnostic and pharmaceutical drug development programs by providing valuable insights into the genomic drivers of genetic diseases and oncology. Additionally, it establishes a genomics data service arm for Genomenon, offering cost-effective variant curation team extensions for genetic testing labs, expediting turnaround times. Boston Genetics, a genomics interpretation and curation company based in the U.S., is part of this acquisition.
Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos.
North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmacogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the pharmacogenomics market by increasing costs of imported sequencing instruments, reagents, analytical software, and high-performance computing components. Research institutions and hospitals in North America and Europe are most affected due to reliance on specialized imported technologies, while Asia-Pacific faces higher costs for genomic tool manufacturing. These tariffs are increasing research expenditures and slowing equipment upgrades. However, they are also encouraging domestic development of sequencing technologies, regional bioinformatics innovation, and localized production of genomic research tools.
The pharmacogenomics market research report is one of a series of new reports that provides pharmacogenomics market statistics, including pharmacogenomics industry global market size, regional shares, competitors with a pharmacogenomics market share, detailed pharmacogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenomics industry. This pharmacogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Pharmacogenomics is a research field that explores how a patient's genes influence their response to medications. Its ultimate goal is to assist doctors in selecting the most appropriate drugs and doses tailored to each individual. Pharmacogenomics is instrumental in developing personalized drugs to address various health conditions, including cardiovascular disease, Alzheimer's disease, cancer, and asthma. The term 'pharmacogenomics marker' refers to a precise medical treatment approach for individuals or specific groups.
Key technologies employed in the pharmacogenomics market include next-generation sequencing (NGS), polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and others. NGS, a massively parallel sequencing technology, offers ultra-high throughput, scalability, and speed, enabling the determination of nucleotide order in entire genomes or specific DNA/RNA regions. Pharmacogenomics applications span neurological diseases, infectious diseases, oncology, cardiovascular diseases, pain management, and various other areas. End-users encompass hospitals and clinics, research institutions, academic institutes, and others.
The pharmacogenomics market includes revenues earned by entities by PennCNV,QuantiSNP, GenoCN and Nexus.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Pharmacogenomics Market Characteristics
3. Pharmacogenomics Market Supply Chain Analysis
4. Global Pharmacogenomics Market Trends and Strategies
5. Pharmacogenomics Market Analysis of End Use Industries
7. Global Pharmacogenomics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Pharmacogenomics Total Addressable Market (TAM) Analysis for the Market
9. Pharmacogenomics Market Segmentation
10. Pharmacogenomics Market Regional and Country Analysis
11. Asia-Pacific Pharmacogenomics Market
12. China Pharmacogenomics Market
13. India Pharmacogenomics Market
14. Japan Pharmacogenomics Market
15. Australia Pharmacogenomics Market
16. Indonesia Pharmacogenomics Market
17. South Korea Pharmacogenomics Market
18. Taiwan Pharmacogenomics Market
19. South East Asia Pharmacogenomics Market
20. Western Europe Pharmacogenomics Market
21. UK Pharmacogenomics Market
22. Germany Pharmacogenomics Market
23. France Pharmacogenomics Market
24. Italy Pharmacogenomics Market
25. Spain Pharmacogenomics Market
26. Eastern Europe Pharmacogenomics Market
27. Russia Pharmacogenomics Market
28. North America Pharmacogenomics Market
29. USA Pharmacogenomics Market
30. Canada Pharmacogenomics Market
31. South America Pharmacogenomics Market
32. Brazil Pharmacogenomics Market
33. Middle East Pharmacogenomics Market
34. Africa Pharmacogenomics Market
36. Pharmacogenomics Market Competitive Landscape and Company Profiles
37. Pharmacogenomics Market Other Major and Innovative Companies
40. Pharmacogenomics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Pharmacogenomics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses pharmacogenomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pharmacogenomics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmacogenomics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology: Next Generation Sequencing; Polymerase Chain Reaction; Gel Electrophoresis; Mass Spectrometry; Microarray; Other Technologies2) By Application: Neurological Diseases; Infectious Diseases; Oncology; Cardiovascular Diseases; Pain Management; Other Applications
3) By End User: Hospitals and Clinics; Research Institutions; Academic Institutes; Other End Users
Subsegments:
1) By Next Generation Sequencing (NGS): Whole Genome Sequencing; Targeted Sequencing; Exome Sequencing2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR); Reverse Transcription PCR (RT-PCR); Digital PCR
3) By Gel Electrophoresis: Agarose Gel Electrophoresis; Polyacrylamide Gel Electrophoresis; Capillary Gel Electrophoresis
4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry); MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight); HRMS (High-Resolution Mass Spectrometry)
5) By Microarray: SNP Microarrays; Expression Microarrays; Comparative Genomic Hybridization (CGH) Arrays
6) By Other Technologies: Sanger Sequencing; CRISPR-Based Technologies; Bioinformatics Tools
Companies Mentioned: Illumina Inc; Eurofins Scientific; Myriad Genetics Inc; PerkinElmer Inc; Centogene N.V; Invitae Corporation; Genomind; Pacific Biosciences of California Inc; Oneome LLC; Admera Health; MapMyGenome; Positive Bioscience; Xcode Life Sciences; Takeda Pharmaceutical Company Limited; Garvan Institute of Medical Research; 3D Medicines Inc; Berry Genomics; BGI; GenomiCare Biotechnology; F Hoffmann-La Roche AG; Merck KGaA; QIAGEN N.V; Centro de Genoma e Biologia de Sistemas; Datar Cancer Genetics Limited; MedGenome Labs; 23andMe; Color Genomics; Pathway Genomics; Genomika Diagnósticos
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Pharmacogenomics market report include:- Illumina Inc
- Eurofins Scientific
- Myriad Genetics Inc
- PerkinElmer Inc
- Centogene N.V
- Invitae Corporation
- Genomind
- Pacific Biosciences of California Inc
- Oneome LLC
- Admera Health
- MapMyGenome
- Positive Bioscience
- Xcode Life Sciences
- Takeda Pharmaceutical Company Limited
- Garvan Institute of Medical Research
- 3D Medicines Inc
- Berry Genomics
- BGI
- GenomiCare Biotechnology
- F Hoffmann-La Roche AG
- Merck KGaA
- QIAGEN N.V
- Centro de Genoma e Biologia de Sistemas
- Datar Cancer Genetics Limited
- MedGenome Labs
- 23andMe
- Color Genomics
- Pathway Genomics
- Genomika Diagnósticos
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 10.85 Billion |
| Forecasted Market Value ( USD | $ 15.98 Billion |
| Compound Annual Growth Rate | 10.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
